After a year of slumping stock prices, Zealand Pharma is striking back, as its peptide drug improved blood sugar control in infants with the rare disease congenital hyperinsulinemia in a phase III trial.
In late 2020, the Danish firm Zealand Pharma A/S hit a big obstacle when its peptide drug dasiglucagon failed to treat the rare condition congenital hyperinsulinism (CHI) in a phase III trial. The company’s stock price dropped by 10% in reaction to the news, and only continued downwards the following year as massive volatility struck biotech stocks around the world.
To read the full article visit Labiotech.eu